Why the study?
Several cancer therapies cause cardiovascular harm that may not manifest until later-phase trials, prompting an assessment of cardiovascular safety monitoring and outcome reporting in contemporary breast cancer trials.
Design
Systematic review of clinical trials
Authors
Loading...
May underestimate real-world CV risks in breast cancer patients; leaves open need for inclusive trials with standardized reporting.
Contemporary later-phase breast cancer trials significantly under-represent patients with cardiovascular conditions and frequently fail to routinely monitor cardiovascular safety, potentially underestimating real-world cardiovascular risks of cancer therapies.
Hamid et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: